Comprehensive analysis of autoantibodies in autoimmune hepatitis using proteomics tool

2011 Fiscal Year Final Research Report

• Project/Area Number: 21590854
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Fukushima Medical University
• Principal Investigator: OHIRA Hiromasa 福島県立医科大学, 医学部, 教授 (90274951)
• Co-Investigator(Kenkyū-buntansha): YOKOKAWA Junjo 福島県立医科大学, 消化器・リウマチ膠原病内科, 非常勤助教 (00453019) ; TAKAHASHI Astushi 福島県立医科大学, 消化器・リウマチ膠原病内科, 助教 (40404868) ; ABE Kazumichi 福島県立医科大学, 消化器・リウマチ膠原病内科, 助教 (30468128)
• Project Period (FY): 2009 – 2011
• Keywords: プロテオソーム / 自己免疫性肝炎 / phosphoenolpyruvate carboxykinase / 自己抗体

Research Abstract

In this study, we analyzed autoantibodies in patients with autoimmune hepatitis(AIH) using proteomics tool. In the process of screening of autoantibodies, phosphoenolpyruvate carboxykinase(PEPCK) protein was identified as a target antigen of an autoantibody from serum of patients with AIH. Anti-PEPCK antibody was positive in 33. 3%(10/30) in patients with AIH, 43. 7%(7/16) in patients with primary biliary cirrhosis(PBC)-AIH overlap and 6%(2/30) in patients with PBC, but not detected in healthy control. This antibody is detected by high frequency in AIH patients and its specificity is high. In conclusion, measurement of anti-PEPCK antibody is considered to be useful for diagnosis of autoimmune hepatitis.